Press Release
SAN FRANCISCO, USA – February 1, 2024
Evidence From First Mahana Tinnitus Study Accepted for Presentation at Upcoming American Audiology Society (AAS) Annual Meeting
Evidence From First Mahana Tinnitus Study Accepted for Presentation at Upcoming American Audiology Society (AAS) Annual Meeting

SAN FRANCISCO, USA - February 1, 2024 – Mahana Therapeutics, a leading provider of digital therapeutics, announced today that positive results from a large US-based Pilot Clinical Trial, have been accepted for presentation at the upcoming American Audiology Society (AAS) Scientific and Technology Meeting, on February 15-17, 2024 in Scottsdale, Arizona. 

The pilot study, one of the largest US-based of its kind with 97 participants, explored the acceptability, safety, and clinical outcomes of Mahana Tinnitus™, which provides Digital Cognitive Behavioral Therapy (CBT) for adults with bothersome tinnitus. 

Clinical outcomes were measured using The Tinnitus Functional Index (TFI) and Tinnitus Primary Function Questionnaire (TPFQ).

The abstract presentation entitled 'Pilot Clinical Trial: Self-Guided CBT-Based Smartphone Program for Tinnitus Management’ will be presented on Friday February 16th 1:30 pm - 3:30 pm (Poster No: 220). 

Co-Author and leading Audiologist, Dr. John Coverstone commented:

‘This pilot study is a significant step toward providing widespread access to evidence-based CBT for people living with tinnitus. The results are extremely encouraging. 69% of those who used more than half the Mahana Tinnitus program experienced clinically significant improvement in Tinnitus as measured by TFI. Further, they saw improvement in tinnitus-related activities such as sleep, anxiety and concentration.’

Key results from the abstract now available online include: 

Simon Levy, CEO and Co-Founder of Mahana Therapeutics, commented:

‘Due to limited availability of therapists, there is significant unmet need for people with tinnitus to access effective CBT and other behavioral interventions, directly via their Hearing Healthcare Practitioners. We are seeing early and rapid adoption of Mahana Tinnitus amongst hearing practitioners, and interest and hope from patients. These results provide further confidence that our unique solution offers a safe and effective companion in hearing care for people living with Tinnitus.’ 

About Mahana Tinnitus

Mahana Tinnitus™ is a new self-guided digital, smartphone enabled program that uses proven techniques to help people reduce the impact of tinnitus on a person’s quality of life. Mahana Tinnitus was created by worldwide experts in tinnitus research and people living with tinnitus. 

About Mahana Therapeutics

Mahana Therapeutics is a leading developer of digital programs that are designed to empower patients with chronic conditions to live fuller lives. The company’s first product, Mahana IBS, was the first digital therapeutic to receive FDA clearance for the treatment of IBS and provides cognitive behavioral therapy (CBT) to adults with IBS. Mahana Tinnitus is a self-guided program that may help people live well with their tinnitus. Mahana Tinnitus has not been evaluated by the FDA.

More information is available at

For more information, contact: